Healthcare analysts and industry groups still don’t know what to expect from the Trump administration’s plan to combat high drug prices, a week after the president announced what he deemed the “most sweeping action in history to lower the price of prescription drugs.”

Trump’s blueprint laid out a series of proposals, but details for several are sparse, and no concrete regulations have been proposed yet.

Recommended Stories

Eli Lilly opposes using imports to tackle high drug prices

Trump’s drug-price crackdown misses the mark, experts say

Cancer groups approach drug price overhaul with caution